{"id":"sublingual-buprenorphine-slb","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Withdrawal symptoms (if discontinued abruptly)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor produces analgesia and reduces opioid withdrawal symptoms with lower abuse potential than full agonists. The sublingual formulation allows rapid absorption through oral mucosa, bypassing first-pass metabolism. Its high receptor binding affinity and ceiling effect on respiratory depression make it safer than full opioid agonists in overdose scenarios.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:02.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Moderate to severe pain management"}]},"trialDetails":[{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sublingual Buprenorphine (SLB)","genericName":"Sublingual Buprenorphine (SLB)","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. Used for Opioid use disorder maintenance treatment, Moderate to severe pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}